Epidermal keratinization + melanogenesis

Category: biosynthesis

Overview

Skin barrier renewal: basal keratinocytes proliferate, differentiate upward through stratum spinosum + granulosum, mature into anucleate corneocytes of stratum corneum, shed (~28-day turnover). Hyperkeratosis (acne, psoriasis, ichthyosis) reflects dysregulated terminal differentiation. AHAs/BHAs accelerate corneocyte shedding (chemical exfoliation): AHAs (glycolic, lactic, mandelic) — water-soluble, surface; BHAs (salicylic) — lipid-soluble, penetrate sebaceous follicles. Melanogenesis in melanocytes: tyrosinase oxidizes tyrosine → DOPA → dopaquinone → eumelanin (brown/black, MC1R-driven) or pheomelanin (red/yellow). Hyperpigmentation Rx blocks tyrosinase (hydroquinone, kojic acid, arbutin) or inhibits melanin transfer (azelaic acid, niacinamide) or downregulates MITF/PAR-2 (tranexamic acid topical, bakuchiol).

Organ Systems

• integumentary

Pathway Steps

1. keratinocyte-basal → corneocyte-shedding — via ~28-day differentiation cascade; AHA/BHA accelerate the desquamation step. Keratinocytes are born in the basal layer and migrate upward, progressively keratinizing into flattened, dead corneocytes that are shed (desquamation) over ~28 days. Disorders of this program cause psoriasis (too fast) and ichthyosis; retinoids and keratolytics modulate it.
2. tyrosine → eumelanin — via tyrosinase oxidation → dopaquinone → polymerization (tyrosinase = melanogenesis target). Melanocytes synthesize melanin from tyrosine via tyrosinase (the rate-limiting enzyme), packaging brown/black eumelanin in melanosomes transferred to keratinocytes for UV protection. Tyrosinase is the target of skin-lightening agents (hydroquinone) and the deficient enzyme in albinism.

Known Modulators

• glycolic acid (activator) — desquamation (AHA, surface). smallest AHA; deepest penetration of AHAs; chemical peel + OTC anti-aging
• lactic acid topical (activator) — desquamation (AHA) + humectant. AHA + draws moisture; less irritating than glycolic; ammonium lactate (Lac-Hydrin) for xerosis
• mandelic acid (activator) — desquamation (AHA, larger molecule). larger AHA → shallower penetration → gentler exfoliation; preferred in melasma + sensitive skin
• salicylic acid topical (activator) — desquamation (BHA, sebaceous follicle penetrant). BHA; lipophilic → penetrates sebum-filled follicles; acne first-line OTC
• hydroquinone (inhibitor) — tyrosinase (melanogenesis). gold-standard skin lightener; ochronosis with prolonged use; OTC 2% restricted; Rx 4%+
• kojic acid (inhibitor) — tyrosinase (copper chelation). fungal metabolite; weaker than hydroquinone but better tolerated; OTC
• azelaic acid (inhibitor) — tyrosinase + acne (broad). rosacea + acne + melasma; topical 15% Rx + 10% OTC
• tranexamic acid topical (inhibitor) — plasmin/PAR-2 axis (melasma). topical for melasma; reduces UV-induced melanocyte activation; cross-link: fibrinolysis for systemic TXA
• bakuchiol (inhibitor) — retinoid-like signaling (gentle alternative). plant-derived; claimed retinol-like benefits without retinoid irritation; less photosensitizing
• niacinamide (inhibitor) — melanosome transfer + barrier repair. vitamin B3 derivative; OTC; reduces melanosome transfer from melanocyte to keratinocyte
• l ascorbic acid topical (inhibitor) — tyrosinase + photoprotection. topical vitamin C 10-20%; oxidation-prone formulation challenges; pH < 3.5 required for absorption

References

• PMID 15564334